

**Otezla® Prior Authorization Request Form (Page 1 of 2)**

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting <b>brand</b>			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information (required)					
<b>Select the diagnosis below:</b>					
<input type="checkbox"/> Active psoriatic arthritis					
<input type="checkbox"/> Moderate to severe plaque psoriasis					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<b>Clinical information:</b>					
Select if Otezla is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Dermatologist <input type="checkbox"/> Rheumatologist					
Will the patient be receiving Otezla in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orenzia (abatacept)]? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For active psoriatic arthritis, also answer the following:</b>					
<b>Reauthorization:</b>					
Is there documentation the patient has had a positive clinical response to Otezla therapy (e.g., improvement in number of swollen/tender joints, pain, or stiffness)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient receiving Otezla in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orenzia (abatacept)]? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For moderate to severe plaque psoriasis, also answer the following:</b>					
Select if the following applies to the patient:					
<input type="checkbox"/> Greater than 10% body surface area involvement					
<input type="checkbox"/> Palmoplantar involvement					
<input type="checkbox"/> Severe scalp psoriasis					
<b>Reauthorization:</b>					
Is there documentation the patient has had a positive clinical response to Otezla therapy (e.g., improvement in body surface area involvement, or Psoriasis Area and Severity Index [PASI] 75 scoring)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient receiving Otezla in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orenzia (abatacept)]? <input type="checkbox"/> Yes <input type="checkbox"/> No					

## Otezla® Prior Authorization Request Form (Page 2 of 2)

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

---



---

Please note: This request may be denied unless all required information is received.  
**Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.**  
**Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.**

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): \_\_\_\_\_ Date: \_\_\_\_\_

**PROACT INTERNAL USE ONLY:**

**Clinical Review Decision**

**Approved, through**

**Denied (documentation attached, if necessary)**

**Tracking:**

1 <sup>st</sup> Attempt		2 <sup>nd</sup> Attempt		Letter Mailed:	
-------------------------	--	-------------------------	--	----------------	--